Welcome to our dedicated page for Agios Pharmaceuticals news (Ticker: AGIO), a resource for investors and traders seeking the latest updates and insights on Agios Pharmaceuticals stock.
Agios Pharmaceuticals, Inc. (Nasdaq: AGIO) generates frequent news as a commercial-stage biopharmaceutical company focused on rare diseases, particularly rare blood disorders. Company updates often center on clinical trial results, regulatory decisions, commercial launches, and financial performance related to its portfolio of small-molecule therapies such as mitapivat.
Readers following AGIO news can expect detailed coverage of developments in the PK activation franchise, including mitapivat in thalassemia, sickle cell disease, and pyruvate kinase (PK) deficiency. Recent announcements have highlighted U.S. Food and Drug Administration (FDA) approval of AQVESME (mitapivat) for anemia in adults with alpha- or beta-thalassemia, positive CHMP opinions in Europe for PYRUKYND (mitapivat) in thalassemia, and topline results from the RISE UP Phase 3 trial in sickle cell disease.
News items also include financial results, such as quarterly revenue from PYRUKYND, updates on cash and investment balances, and commentary on research and development spending. Corporate communications frequently discuss anticipated milestones for ongoing trials of tebapivat, AG-236, and AG-181, as well as strategic priorities to advance Agios’ rare disease portfolio.
Investors and observers can use this page to track AGIO press releases on regulatory interactions, Risk Evaluation and Mitigation Strategy (REMS) implementation for AQVESME, partnerships for commercialization in Europe and the Middle East, and presentations at major medical and investor conferences. Bookmark this news feed to monitor how clinical data, approvals, and commercial execution shape the outlook for Agios Pharmaceuticals within the rare disease and hematology landscape.
Agios Pharmaceuticals (Nasdaq: AGIO) will present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024, at 1:20 p.m. ET. The company, known for its work in cellular metabolism and PK activation for rare diseases, will have its presentation webcast live on its website. The replay of this webcast will be available for at least two weeks post-event.
Agios Pharmaceuticals (Nasdaq: AGIO) announced a $905 million purchase agreement with Royalty Pharma for the acquisition of its 15% royalty on potential U.S. net sales of vorasidenib, an oral dual inhibitor for IDH-mutant diffuse glioma. Upon FDA approval of vorasidenib, Agios will receive an upfront payment of $905 million and retain rights to a $200 million milestone payment from Servier, totaling $1.1 billion. The PDUFA action date is set for August 20, 2024. Agios will maintain a 3% royalty on annual U.S. net sales over $1 billion. This transaction is expected to boost Agios' financial flexibility and support future product launches and pipeline expansion.
Agios Pharmaceuticals announced it will present key clinical and translational data on rare blood disorders at the European Hematology Association 2024 Hybrid Congress in Madrid from June 13-16, 2024.
The presentations will include data from the Phase 3 ENERGIZE study of mitapivat in non-transfusion-dependent thalassemia, highlighting efficacy and safety results.
Additional sessions will cover quality of life data from ENERGIZE and the design of the Phase 3 RISE UP study for sickle cell disease.
Agios will also share real-world data on pyruvate kinase deficiency and explore mitapivat's potential in other rare hemolytic anemias.
The company will host a virtual investor event on June 16, 2024, to discuss these findings.
Agios Pharmaceuticals, a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, will present at the BofA Securities 2024 Health Care Conference on May 16, 2024. The presentation will be live-streamed on the company's website, with a replay available for at least two weeks.
Agios Pharmaceuticals, Inc. (Nasdaq: AGIO) will be presenting at the RBC Capital Markets Global Healthcare Conference on May 14, 2024. The presentation is scheduled for 8:00 a.m. ET and will focus on the company's innovative therapies for rare diseases. Investors can access the live webcast on the company's website and a replay will be available for two weeks after the event.
Agios Pharmaceuticals, Inc. reported positive results from the Phase 3 ENERGIZE study of mitapivat in thalassemia. Mitapivat has potential as the first approved therapy for all thalassemia subtypes. The company posted $8.2 million in net revenue for PYRUKYND® in Q1 2024. Agios also disclosed upcoming milestones in sickle cell disease, pediatric PK deficiency, and lower-risk Myelodysplastic Syndromes. Financially, the company had $714.3 million in cash, cash equivalents, and marketable securities as of March 31, 2024. Agios aims to fund operations until at least 2026.
Summary not available.
Summary not available.
Summary not available.
Summary not available.